TECTONIC THERAPEUTIC, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
TECTONIC THERAPEUTIC, INC. (TECX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.01M, a 55.02% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.21M, a 52.40% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.82M, a 70.73% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.59M, a 542.18% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.50M, a 200.69% increase from fiscal 2024.
- TECTONIC THERAPEUTIC, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $3.49M, a 211.42% increase from fiscal 2023.
- TECTONIC THERAPEUTIC, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.12M, a 90.27% decline from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $11.52M, a 37.98% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.01M 10-Q · filed 2026-08-06 | $7.22M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $3.21M 10-Q · filed 2026-08-06 | |||||
| 2025-12-31 | $10.50M 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | $2.82M 10-Q · filed 2025-11-06 | $5.41M derived: sum of 2 quarters · filed 2026-08-06 | $7.51M derived: sum of 3 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $2.59M 10-Q · filed 2026-08-06 | $4.69M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $2.10M 10-Q · filed 2026-08-06 | |||||
| 2024-12-31 | $3.49M 10-K · filed 2026-02-26 | |||||
| 2024-09-30 | $1.65M 10-Q · filed 2025-11-06 | $2.05M derived: sum of 2 quarters · filed 2025-11-06 | $2.37M derived: sum of 3 quarters · filed 2025-11-06 | -$2.79M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $403.00K 10-Q · filed 2025-11-06 | $724.00K derived: sum of 2 quarters · filed 2025-11-06 | -$4.44M derived: sum of 3 quarters · filed 2025-11-06 | -$4.16M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $321.00K 10-Q · filed 2025-11-06 | $878.00K 10-Q · filed 2024-05-09 | -$4.84M derived: sum of 2 quarters · filed 2025-11-06 | -$4.57M derived: sum of 3 quarters · filed 2025-11-06 | -$4.29M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2023-12-31 | -$5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$4.89M derived: sum of 2 quarters · filed 2025-03-20 | -$4.61M derived: sum of 3 quarters · filed 2025-03-20 | $1.12M 10-K · filed 2025-03-20 | $6.89M 10-K · filed 2024-03-14 | |
| 2023-09-30 | $275.00K 10-Q · filed 2024-11-12 | $2.22M 10-Q · filed 2023-11-09 | $552.00K derived: sum of 2 quarters · filed 2024-11-12 | $6.28M 10-Q · filed 2023-11-09 | $3.08M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $277.00K 10-Q · filed 2024-11-12 | $1.53M 10-Q · filed 2023-08-10 | $4.06M 10-Q · filed 2023-08-10 | $2.81M derived: sum of 3 quarters · filed 2024-11-12 | $5.46M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-03-31 | $275.00K 10-Q · filed 2024-11-12 | $2.53M 10-Q · filed 2023-05-11 | $2.53M derived: sum of 2 quarters · filed 2024-11-12 | $5.19M derived: sum of 3 quarters · filed 2024-11-12 | $8.42M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2022-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $4.91M derived: sum of 2 quarters · filed 2024-03-14 | $8.14M derived: sum of 3 quarters · filed 2024-03-14 | $11.52M 10-K · filed 2024-03-14 | ||
| 2022-09-30 | $2.66M 10-Q · filed 2023-11-09 | $5.89M derived: sum of 2 quarters · filed 2023-11-09 | $9.27M 10-Q · filed 2023-11-09 | $13.35M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $3.23M 10-Q · filed 2023-08-10 | $6.61M 10-Q · filed 2023-08-10 | $10.70M derived: sum of 3 quarters · filed 2023-08-10 | $15.87M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $3.38M 10-Q · filed 2023-05-11 | $7.46M derived: sum of 2 quarters · filed 2023-05-11 | $12.63M derived: sum of 3 quarters · filed 2023-05-11 | $17.32M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $9.25M derived: sum of 2 quarters · filed 2023-03-23 | $13.94M derived: sum of 3 quarters · filed 2023-03-23 | $18.58M 10-K · filed 2023-03-23 | ||
| 2021-09-30 | $5.17M 10-Q · filed 2022-11-08 | $9.86M derived: sum of 2 quarters · filed 2022-11-08 | $14.49M 10-Q · filed 2022-11-08 | $18.60M derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $4.69M 10-Q · filed 2022-08-09 | $9.33M 10-Q · filed 2022-08-09 | $13.43M derived: sum of 3 quarters · filed 2022-08-09 | $18.23M derived: sum of 4 quarters · filed 2022-08-09 | ||
| 2021-03-31 | $4.63M 10-Q · filed 2022-05-10 | $8.74M derived: sum of 2 quarters · filed 2022-05-10 | $13.54M derived: sum of 3 quarters · filed 2022-05-10 | $17.44M derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $8.91M derived: sum of 2 quarters · filed 2022-03-17 | $12.81M derived: sum of 3 quarters · filed 2022-03-17 | $15.63M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $4.80M 10-Q · filed 2021-11-04 | $8.70M derived: sum of 2 quarters · filed 2021-11-04 | $11.53M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $3.90M 10-Q · filed 2021-08-05 | $6.72M 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | $2.82M 10-Q · filed 2021-05-13 | |||||
| 2019-12-31 | $6.80M 10-K · filed 2021-03-18 | |||||
| 2019-09-30 | $1.80M 10-Q · filed 2020-11-05 | $3.46M derived: sum of 2 quarters · filed 2020-11-05 | $4.92M derived: sum of 3 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $1.66M 10-Q · filed 2020-11-05 | $3.12M derived: sum of 2 quarters · filed 2020-11-05 | ||||
| 2019-03-31 | $1.46M 10-Q · filed 2020-11-05 | |||||
| 2018-12-31 | $2.20M 10-K · filed 2020-03-16 | |||||
| 2018-09-30 | $550.00K 10-Q · filed 2019-11-07 | $1.01M derived: sum of 2 quarters · filed 2019-11-07 | $1.12M derived: sum of 3 quarters · filed 2019-11-07 | |||
| 2018-06-30 | $457.00K 10-Q · filed 2019-11-07 | $566.00K derived: sum of 2 quarters · filed 2019-11-07 | ||||
| 2018-03-31 | $109.00K 10-Q · filed 2019-11-07 | |||||
| 2017-12-31 | $109.00K 10-K · filed 2019-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |